Integral Molecular, Inc. Announces Patent Allowance For Dengue Research Technology

PHILADELPHIA--(BUSINESS WIRE)--Integral Molecular, a leader in membrane protein research, announces the issuance of a new composition patent protecting dengue reporter virus particles (RVPs). The invention relates to the company’s chimeric and codon-optimized flavivirus replicons, expression plasmids, and RVPs used for infectivity, neutralization, enhancement and structure-function studies of dengue virus (DENV) and its envelope protein (prM/E). U.S. Patent No 8,691,961, was issued by the USPTO on April 8, 2014, furthering the company’s commitment to the discovery of drugs and vaccines against this widespread virus.

Help employers find you! Check out all the jobs and post your resume.